First Tracks Biotherapeutics Inc. Ordinary Shares (TRAX)

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Graham-style investor, I start with what is proven. First Tracks is a clinical-stage immunology company with three pipeline candidates and 104 employees, but in the filed quarters it has no revenue. In fiscal Q2 2026, the quarter ended 2026-06-30, net income was -$33.4M and diluted EPS -$0.95; in fiscal Q1 2026, the quarter ended 2026-03-31, net income was -$50.5M. The year-over-year Q2 loss narrowed from -$42.4M in fiscal Q2 2025, but Q1 worsened from -$47.2M in fiscal Q1 2025. FairStock shows TTM free cash flow of -$148.2M and FCF yield -12.0%, so cash consumption is real. The balance sheet looks low-levered with D/E 0.03, and FairStock's Altman Z-score is 54.76, but Piotroski is only 1/9, signaling weak fundamental momentum. At the 2026-10-16 close of $34.46, FairStock calculates P/E -7.32, P/B 4.67, ROE -48.92%, and ROCE -28.97%. A $1.2B market cap on no revenue and negative earnings gives no Graham margin of safety; the value rests on binary clinical success, not current cash flows. The Lynch category is none because only 0 years of filed annual results are available, needing 3. I can admire the science and low debt, but I cannot call this a defensible moat or a statistically cheap business; it is a speculative pipeline valuation.

In plain English: First Tracks Biotherapeutics is a clinical-stage biotech company working on immune therapies for autoimmune and inflammatory diseases. It has no reported revenue in the filed quarters and is burning cash, though it carries very little debt. At $34.46 on 2026-10-16, the price looks expensive relative to the company's accounting value and there are no profits to support it; the value depends on future drug trial success.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-16 close · note generated 2026-10-20 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · fiscal Q1 2025 10-Q (period ended 2025-03-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer